ADVANZ PHARMA Releases Environmental, Social & Governance (ESG) Report for 2023-2024

• ADVANZ PHARMA releases its 2023-2024 ESG report reinforcing its commitment to sustainability.
• The report is structured across our three strategic ESG pillars: focusing on patients' needs; ensuring sustainable and responsible operations and growth; and developing our people.

London, UK - 04/10/2024: - ADVANZ PHARMA Holdco Limited ("ADVANZ PHARMA" or "the Company"), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital and rare disease medicines in Europe, Canada, and Australia, is pleased to announce the release of its latest Environmental, Social & Governance (ESG) report, outlining ADVANZ PHARMA's ongoing dedication to environmental stewardship, social responsibility and ethical practices.

This report is an interim update following last year's comprehensive statement. Key achievements highlighted in the report include:

• Focusing on patients' needs: With its medicines, ADVANZ PHARMA has reached ~236m patients from May 2023 to April 2024. In its mission to improve patients' lives, ADVANZ PHARMA continues to undertake various activities focused on providing new or enhanced treatment options and holistic support to patients and healthcare professionals (HCPs).

• Ensuring sustainable and responsible operations and growth: In 2023, the company has decreased its Scope 2 (market-based) emissions by 51% by moving to renewable energy contracts and undertaken a climate scenario analysis to identify climate-related risks and opportunities. The company is also actively engaging with its suppliers on ESG topics and performance against ESG metrics is a criterion in the selection process of new contract manufacturing organisations.

• Developing our people: We are proud to see the progress we are making on our people and culture journey, achieving a 50% representation of women across the organisation in 2023 and the launch of a new Talent development strategy and training programme. The overall employee engagement score remains very high at 89%.

Steffen Wagner, CEO of ADVANZ PHARMA, said, "Sustainability and patient-centricity will remain key for ADVANZ PHARMA as we drive positive change and make a difference in the lives of patients around the world."

The release of ADVANZ PHARMA's latest ESG report reinforces the company's transparency and accountability in pursuing its ESG goals.